📊 MANE Key Takeaways
Is Veradermics, Inc (MANE) a Good Investment?
Veradermics is a pre-revenue pharmaceutical company with severe financial distress characterized by negative stockholders' equity of -$121.0M, indicating the company is technically insolvent. The company is burning significant cash with negative operating cash flow of -$71.6M and lacks meaningful revenue generation, making it a high-risk speculative investment with uncertain path to profitability.
Fundamentals appear very weak: the company has no reported revenue, deeply negative operating cash flow, and substantial ongoing losses, which indicate a business still dependent on external financing rather than self-sustaining operations. While liquidity looks strong on a current-ratio basis, the cash balance is modest relative to annual cash burn, and the reported negative equity warning further weakens financial quality.
Why Buy Veradermics, Inc Stock? MANE Key Strengths
- Strong liquidity position with current ratio of 16.66x and $21.8M in cash reserves providing near-term operational runway
- Moderate debt burden with total liabilities of only $9.2M relative to total assets of $152.6M
- Pharmaceutical sector offers potential for significant upside if development programs succeed
- Strong near-term liquidity ratios suggest limited immediate balance sheet pressure
- Low reported liabilities reduce traditional debt-servicing risk
- Net loss improved year over year, indicating some cost-control progress
MANE Stock Risks: Veradermics, Inc Investment Risks
- Negative stockholders' equity of -$121.0M indicates technical insolvency and shareholder equity destruction
- No revenue generation with significant operating losses of -$72.3M suggesting product pipeline has not commercialized
- Rapidly deteriorating cash position with -$71.6M operating cash flow burn rate; current cash may sustain operations for 3-4 quarters at most without financing
- Negative ROA of -45.9% demonstrates severe asset inefficiency and value destruction
- Diluted EPS of -$111.91 with 202.1% YoY deterioration indicates massive shareholder value erosion and likely significant dilution from future financing
- No revenue base means fundamentals are not yet supported by commercial execution
- Large operating and free cash flow losses imply continued cash burn and likely future capital raises
- Negative stockholders equity warning signals weak balance sheet quality and reduces financial flexibility
Key Metrics to Watch
- Path to revenue generation and product commercialization timelines
- Monthly cash burn rate and projected runway to next financing event
- Clinical trial progress and regulatory approvals for pipeline assets
- Subsequent financing activities and dilution impact on existing shareholders
- Total assets composition and impairment risks to intangible assets
- Quarterly operating cash burn versus cash and equivalents
- Revenue generation or milestone progress toward commercialization
Veradermics, Inc (MANE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.66x current ratio provides a solid financial cushion.
MANE Profit Margin, ROE & Profitability Analysis
MANE vs Healthcare Sector: How Veradermics, Inc Compares
How Veradermics, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Veradermics, Inc Stock Overvalued? MANE Valuation Analysis 2026
Based on fundamental analysis, Veradermics, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Veradermics, Inc Balance Sheet: MANE Debt, Cash & Liquidity
MANE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Veradermics, Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-37.05 indicates the company is currently unprofitable.
MANE Revenue Growth, EPS Growth & YoY Performance
Veradermics, Inc Dividends, Buybacks & Capital Allocation
MANE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Veradermics, Inc (CIK: 0001827635)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MANE
What is the AI rating for MANE?
Veradermics, Inc (MANE) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MANE's key strengths?
Claude: Strong liquidity position with current ratio of 16.66x and $21.8M in cash reserves providing near-term operational runway. Moderate debt burden with total liabilities of only $9.2M relative to total assets of $152.6M. ChatGPT: Strong near-term liquidity ratios suggest limited immediate balance sheet pressure. Low reported liabilities reduce traditional debt-servicing risk.
What are the risks of investing in MANE?
Claude: Negative stockholders' equity of -$121.0M indicates technical insolvency and shareholder equity destruction. No revenue generation with significant operating losses of -$72.3M suggesting product pipeline has not commercialized. ChatGPT: No revenue base means fundamentals are not yet supported by commercial execution. Large operating and free cash flow losses imply continued cash burn and likely future capital raises.
What is MANE's revenue and growth?
Veradermics, Inc reported revenue of N/A.
Does MANE pay dividends?
Veradermics, Inc does not currently pay dividends.
Where can I find MANE SEC filings?
Official SEC filings for Veradermics, Inc (CIK: 0001827635) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MANE's EPS?
Veradermics, Inc has a diluted EPS of $-111.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MANE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Veradermics, Inc has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MANE stock overvalued or undervalued?
Valuation metrics for MANE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MANE stock in 2026?
Our dual AI analysis gives Veradermics, Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MANE's free cash flow?
Veradermics, Inc's operating cash flow is $-71.6M, with capital expenditures of $24.0K.
How does MANE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 16.66 (avg: 2).